Nifurpipone

Nifurpipone is an orally active broad-spectrum antimicrobial agent. Nifurpipone acts against Gram-positive and Gram-negative bacteria, and reduces bacterial loads in systemic, intramuscular and urinary tract infections in mouse models. Nifurpipone can be used in studies related to systemic infections and urinary tract infections^[1][2]. In Vitro:Nifurpipone (Compound 13) (2.5-160 units) exhibits in vitro antibacterial activity against Escherichia coli 100 (40), Salmonella typhimurium 1090 (40), Pseudomonas aeruginosa H2 (160), Proteus vulgaris OX (80), Micrococcus pyogenes SG511 (20), Streptococcus pyogenes A88 (2.5), and Bacillus subtilis ATCC 9466 (20)^[1].
Nifurpipone exhibits antibacterial activity against a variety of Gram-negative and Gram-positive bacteria in vitro, with MIC values ranging from 5 to 160 μg/mL under standard conditions, and retains most of its activity in the presence of 10% bovine serum^[2].
Nifurpipone inhibits most of the 70 clinical urinary tract infection strains at a level of MIC ≤100 μg/mL, with the strongest activity against strains of the genera Klebsiella-Enterobacter and Proteus^[2].
The in vitro antibacterial activity of Nifurpipone against Staphylococcus aureus SG 511 increases with rising pH, and its MIC value decreases by 100-fold over the pH range of 5 to 8^[2]. In Vivo:Nifurpipone exhibits in vivo antibacterial activity against systemic *Streptococcus pyogenes* infection, systemic *Salmonella typhimurium* infection, and intramuscular *Staphylococcus aureus* infection in mice. Depending on the pathogen, its activity is comparable to or higher than that of nitrofurantoin^[1].
Nifurpipone exhibits in vivo antibacterial activity against ascending Proteus vulgaris urinary tract infection in rats^[1].